Genetic polymorphism in CYP17 and breast cancer risk in Japanese women.

[1]  B. Ponder,et al.  A Systematic Review Of Genetic Polymorphisms and Breast Cancer Risk 1 , 2000 .

[2]  Chen-Yang Shen,et al.  Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. , 1999, Cancer research.

[3]  M. Gentile,et al.  Association between CYP17 gene polymorphism and risk of breast cancer in young women , 1999, International journal of cancer.

[4]  P. Lønning,et al.  CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. , 1999, Cancer research.

[5]  W. Willett,et al.  The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. , 1999, Cancer research.

[6]  K. Buetow,et al.  Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk , 1999, British Journal of Cancer.

[7]  I. Bleiweiss,et al.  CYP17 genotype and breast cancer risk. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  D. Bell,et al.  Association between CYP17 polymorphisms and the development of breast cancer. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  B. Ponder,et al.  No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. , 1998, British Journal of Cancer.

[10]  M. Pike,et al.  Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. , 1998, Cancer research.

[11]  S. Ueda,et al.  Combined polymorphism associated with a 3-bp deletion in the 5'-flanking region of a tetrameric short tandem repeat at the CYP19 locus. , 1997, Nihon hoigaku zasshi = The Japanese journal of legal medicine.

[12]  G. Coetzee,et al.  A polymorphism in the CYP17 gene increases the risk of breast cancer. , 1997, Cancer research.

[13]  M. Toi,et al.  [Determination of intratumoral estrone (E1) and estradiol (E2) in primary breast cancer tissues by sensitive HPLC-RIA]. , 1997, Gan to kagaku ryoho. Cancer & chemotherapy.

[14]  J. Little,et al.  Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. , 1994, Human molecular genetics.

[15]  J. Kelsey.  Breast cancer epidemiology: summary and future directions. , 1993, Epidemiologic reviews.

[16]  S. Yuasa,et al.  Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: Associations and interactions in an international case‐control study , 1990, International journal of cancer.

[17]  J L Kelsey,et al.  Breast cancer epidemiology. , 1988, Cancer research.

[18]  M. Waterman,et al.  Expression of bovine 17 alpha-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells. , 1986, Science.

[19]  D. Kiang,et al.  Metabolism of pregnenolone by human breast cancer. Evidence for 17α-hydroxylase and 17,20-lyase , 1979, Steroids.